Advertisement

Topics

A-Viral ASA Company Profile

10:37 EDT 19th September 2018 | BioPortfolio

The company was formally registered in 1986, but there were little activity until 1997. Then the company acquired its first patent application. The company had its first major public offering in the fall of 1998, at the same time when Einar Stokke became CEO. Since then more than 7 million Euros has been used for research, by far the major part of it on AV 1101.Numerous laboratory tests took place at the National Institute of Public Health in Oslo from 1998. Later laboratory testing has shifted towards our research partner, CLB-Sanquin in Amsterdam , which has been the centre for our lab. research for several years now.
Through studies of OxyPhenylButazone (OBP) AV 1101 was discovered. AV 1101 is 4-Hydroxy-OxyPhenylButazone. The chemical itself is known through literature only as a metabolite from PhenylButazone (PB), and A-Viral has a patent application for AV 1101 and many closely related forms for all therapeutic use in humans and animals. AV 1101 has recently acquired a patent grant in USA for use against inflammatory and autoimmune diseases.
(read more: Patents)
In 2001 A-Viral started to have its lab research done at CLB – Sanquin. A research group under professor Lucien Aarden (specialist in cellular immunology) started the work to find the basic functions of AV 1101. They perform a lot of testing with AV 1101, and measures how various blood cells react to AV 1101 under different conditions, measuring cell activation, proliferation and cytokine production. In the beginning they also tested on how HIV would propagate in the presence of AV 1101. They have also checked out metabolites of and conjugates from AV 1101, and tested which are still active. Assays for measuring AV 1101 in blood have been developed. New related substances are synthesized and tested, etc. This research is the basis for our understanding of AV 1101, and it is the platform on which we build our clinical research. And our team at CLB does additional analysis with blood samples from our clinical studies, retrieving important information about the function of AV 1101

Location

Postboks 1780
Vika
Oslo
122
Norway

Contact

Phone: 47 23118953
Fax: 47 23118959
Email: bjorn.ivar@gmail.com


News Articles [369 Associated News Articles listed on BioPortfolio]

GE creates ready-to-run factory for viral vector drugs

GE Healthcare has created a ‘factory-in-a-box’ facility for the production of viral vector-based drugs, including viral vector vaccines, oncolytic viruses,...Read More... The post GE creat...

New uses for existing antiviral drugs

(Norwegian University of Science and Technology) Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming. Testing existing anti-vira...

People who don’t read the news better at predicting which articles will go viral

Figuring out how to make articles and videos go viral is the holy grail for any content creator. Although a magic formula remains elusive, in recent years, neuroscientists have forecasted which conten

Medical News Today: What are the symptoms of viral pneumonia?

Viral pneumonia causes symptoms that include a cough, fever, and chills. It often occurs as a complication of the common cold. Those more at risk include young children and older adults. The condition...

HIV viral suppression rates nearly triples with ART use in US

A new study funded by the National Institutes of Health (NIH) has revealed that HIV viral suppression rates have nearly...Read More... The post HIV viral suppression rates nearly triples with ART use ...

Radiance could be the key to faster viral detection

Researchers have analysed viruses through Radiance, an instrument designed to improve the process of analysing viruses and viral detection... The post Radiance could be the key to faster viral detecti...

QoL in Adolescents With HCV Treated With Sofosbuvir+Ribavirin

How does treatment with DAAs and viral eradication affect health-related quality of life in adolescent patients with HCV? Journal of Viral Hepatitis

#jobs #lifescience Postdoctoral Researcher on Viral Oncology

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Postdoctoral Researcher on Viral Oncology .A postdoctoral research position i...

Drugs and Medications [19 Associated Drugs and Medications listed on BioPortfolio]

Zovirax [BTA PHARMACEUTICALS INC]

ZOVIRAX (acyclovir) Ointment 5%

Zovirax [BTA PHARMACEUTICALS INC]

ZOVIRAX (acyclovir) Cream 5%USE ONLY FOR COLD SORES

Denavir [New American Therapeutics, Inc]

Denavir BRAND OF penciclovir cream, 1% For Dermatologic Use Only Rx only

Denavir [Novartis Consumer Health, Inc.]

Denavir

Denavir [Physicians Total Care, Inc.]

Denavir

PubMed Articles [924 Associated PubMed Articles listed on BioPortfolio]

Viral Hepatitis and Acute Liver Failure: Still a Problem.

Although the overall prevalence is on the decline, viral hepatitis still plays a major role in the development of acute liver failure (ALF) worldwide. Hepatitis A, B, D, and E contribute to most fulmi...

Pleiotropic roles of the ubiquitin-proteasome system during viral propagation.

Protein ubiquitination is a highly conserved post-translational modification affecting various biological processes including viral propagation. Ubiquitination has multiple effects on viral propagatio...

Extreme heterogeneity of influenza virus infection in single cells.

Viral infection can dramatically alter a cell's transcriptome. However, these changes have mostly been studied by bulk measurements on many cells. Here we use single-cell mRNA sequencing to examine th...

Identification of viral domains integrated into Arabidopsis proteome.

Horizontal gene transfer (HGT) contributes to the genome evolution of living organisms. In particular, several recent studies provide convincing data on the integration of viral sequences into diverse...

A Talented Duo: IFIT1 and IFIT3 Patrol Viral RNA Caps.

Hosts respond to viral infection by expressing interferon-stimulated genes, of which IFITs are potent inhibitors of viral RNA translation. Johnson et al. (2018) solved the structure of the IFIT1-IFIT...

Clinical Trials [1128 Associated Clinical Trials listed on BioPortfolio]

Third Party Anti-Viral Cytotoxic T-Cells

The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infect...

FST-100 in the Treatment of Acute Viral Conjunctivitis

This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute viral conjunctivitis. The study intends to sh...

Intensive Viral Dynamics Substudy of A5248

The HIV integrase inhibitor, raltegravir (RAL), which was recently approved by the FDA, has been shown in several trials to be highly effective. The main study will estimate the viral load...

Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children

The purpose of this study is to determine whether a protein called TREM-1 can be used to differentiate viral and bacterial pneumonias in children who are on ventilator support. We propose ...

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

The purpose of this study is to see if adding 1 drug to an anti-HIV drug combination early in treatment against HIV can lower the viral load (amount of HIV in the blood) to a level so low ...

Companies [216 Associated Companies listed on BioPortfolio]

Virus Detection & Diagnostics Virinova

Our unique and proprietory diagnostic technology enables the detection and quantification of viruses without the use of PCR or antibodies - Direct detection of viruses and viral particles - F...

Brickfish®

Brickfish® is the performance-based Cost Per Engagement® (CPE®) social media solution that has generated 300 million consumer engagements and conversations for advertisin...

Cavit Sciences

Cavit Sciences, Inc. (“Cavit”) is a biotechnology company engaged in developing treatments of cancer and viral infections. Our strategy is to develop and commercialize intellectual property right...

NanoViricides, Inc.

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricid...

Molecular Medicine BioServices (

Molecular Medicine BioServices (MMB) is dedicated to providing a variety of development, manufacturing, and ancillary services for the viral vaccine and viral therapeutic marketplace. In this exciting...

More Information about "A-Viral ASA" on BioPortfolio

We have published hundreds of A-Viral ASA news stories on BioPortfolio along with dozens of A-Viral ASA Clinical Trials and PubMed Articles about A-Viral ASA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A-Viral ASA Companies in our database. You can also find out about relevant A-Viral ASA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record